- Atlas
- Medicine & Health
- Clinical Immunology
Clinical Immunology
Clinical immunology is the branch of medicine that deals with diseases caused by the immune system itself—when it fails, when it attacks the body, when it overreacts to harmless things, or when it must be deliberately restrained or redirected.
9 frameworks, from 1897 to today · Immunology · Medicine & Health
- Immunochemistry and serological diagnosis 1897-1980
- Serum therapy and serum sickness 1902-1930
- Autoimmunity 1942-Present
- Transplantation immunology and immunosuppression 1945-Present
- Primary immunodeficiency 1952-Present
- IgE-mediated allergy model 1966-Present
- Cellular and molecular immunodiagnostics 1975-Present
- Biologic and targeted immunotherapy 1997-Present
- Precision immunodiagnostics 2010-Present
Overview
Clinical immunology is the branch of medicine that deals with diseases caused by the immune system itself—when it fails, when it attacks the body, when it overreacts to harmless things, or when it must be deliberately restrained or redirected. Its practitioners diagnose immune disorders in the laboratory, treat patients with everything from antihistamines to engineered antibodies, and manage the consequences of replacing or suppressing immunity. What is at stake is unusually direct: the field's central problems—why some people cannot fight infection, why others attack their own tissues, why a transplant is rejected—are questions that determine whether patients live or die. Its history is the story of how clinical observation and laboratory science became inseparable, and how a set of practical problems (serum therapy, transfusion, transplantation, allergy) forced medicine to build an immunology it could use.
Serum Sickness and the First Clinical Immune Reactions
Clinical immunology began as a side effect. In the 1890s, Emil von Behring and Shibasaburo Kitasato showed that the blood serum of animals immunized against diphtheria or tetanus could protect other animals, and serum therapy became the first effective treatment for these diseases12. But when patients received large doses of foreign serum—horse serum was standard—some developed a characteristic illness days to weeks later: fever, rash, joint pain, and swollen lymph nodes. This was serum sickness, described in the early twentieth century, and it was among the first recognized human immune reactions to a therapeutic agent. The explanation came from the new science of anaphylaxis: Charles Richet and Paul Portier had shown in 1902 that a second dose of a foreign protein could produce a violent, sometimes fatal reaction in a previously sensitized animal3. Serum sickness and anaphylaxis taught clinicians that the immune response itself could injure the patient, and that the timing and dose of exposure mattered. The practical lesson—that foreign proteins were dangerous—shaped the cautious, dose-escalating approach to biological therapy that persists today.
Immunochemistry and the Serological Laboratory
The clinical laboratory was built on immunochemistry, the chemistry of antibody–antigen reactions. In 1897, Rudolf Kraus showed that mixing antibody-containing serum with its antigen produced a visible precipitate, and this principle became the basis of diagnostic tests. The Wassermann test for syphilis, introduced in 1906, used complement fixation—a method in which the presence of antibody–antigen complexes consumes complement, and the consumption is detected by whether red blood cells are later lysed. The test was imperfect (it could give false positives in other conditions), but it established the model: a patient's serum could be interrogated with a known antigen, and the result read as a clinical fact. Around the same period, Karl Landsteiner's work on blood groups (1901) showed that antibodies against foreign red-cell antigens were a natural, predictable part of human serum, and that matching donor and recipient was a matter of serology. By the mid-twentieth century, techniques such as immunodiffusion (in which antigen and antibody diffuse toward each other in a gel and form visible lines of precipitation) and immunoelectrophoresis allowed clinicians to identify specific proteins in patients' serum—for example, the monoclonal "M-spike" of multiple myeloma. These methods made the immune system visible in the clinic, and they set the pattern for every later generation of immunodiagnostics.
Autoimmunity and the Diagnostic Autoantibody
The idea that the immune system could attack the self was resisted for decades. Paul Ehrlich's concept of horror autotoxicus—the notion that the body would not produce antibodies against its own tissues—framed autoimmunity as implausible4. The evidence accumulated anyway. In 1904, Julius Donath and Karl Landsteiner explained paroxysmal cold hemoglobinuria as an autoantibody that bound red cells in the cold and lysed them when warmed. In 1942, Albert Coons developed immunofluorescence, using antibodies labeled with a fluorescent dye to stain tissues under the microscope; this made it possible to see antibodies bound to tissue in patients. The decisive clinical case was the LE cell phenomenon, described by Malcolm Hargraves and colleagues in 1948: a neutrophil that had engulfed the nuclear material of another cell, seen in the blood of patients with systemic lupus erythematosus. This was direct evidence of an autoantibody against the cell nucleus. The discovery of rheumatoid factor (an antibody against immunoglobulin) in the 1940s and the description of anti-nuclear antibodies in lupus in the 1950s turned autoimmunity from a theoretical worry into a diagnostic category. Clinical immunology now had a set of tests—immunofluorescence on tissue sections, agglutination assays, and later enzyme-linked immunosorbent assays (ELISA)—that could identify specific autoantibodies and link them to specific diseases. The diagnostic autoantibody became the field's signature tool.
Primary Immunodeficiency as a Natural Experiment
When a child is born without a working part of the immune system, the resulting illness is a natural experiment that reveals what that part does. In 1952, Ogden Bruton described a boy with recurrent bacterial infections who lacked gamma globulin in his serum; this was X-linked agammaglobulinemia, the first recognized primary immunodeficiency. Bruton treated the boy with pooled human immunoglobulin, and the success of this replacement therapy established a principle: if a component is missing, replace it. In the 1960s and 1970s, DiGeorge syndrome (thymic hypoplasia, with defective T-cell immunity) and severe combined immunodeficiency (SCID)—in which both antibody and cellular immunity fail—were characterized, and the study of these patients clarified the division of labor between B cells (antibody) and T cells (cellular immunity). The 1970s also brought adenosine deaminase (ADA) deficiency, a form of SCID caused by a missing enzyme; in 1990, the first gene therapy attempt in humans was performed on a child with ADA-SCID. Primary immunodeficiencies taught clinicians that the immune system is modular—that a single missing molecule can produce a specific, predictable vulnerability—and they provided the clinical proof that the cellular architecture of immunity described in the laboratory was real.
Transplantation and the Problem of Rejection
Skin grafting experiments in the 1940s by Peter Medawar and colleagues showed that rejection of a foreign graft was an immunological event: a second graft from the same donor was rejected faster than the first, the hallmark of immunological memory. The discovery of the major histocompatibility complex (MHC) in mice (by George Snell and others) and the human leukocyte antigen (HLA) system in humans (by Jean Dausset and others in the 1950s and 1960s) explained why: the immune system recognizes foreign tissue by the MHC molecules on its cells. Clinical transplantation became possible when immunosuppression became possible. Azathioprine, introduced in the early 1960s, and cyclosporine, introduced in the late 1970s, allowed kidneys and then hearts and livers to be transplanted with acceptable survival. The clinical problem drove the science: to prevent rejection, clinicians had to understand T-cell activation, and the drugs they used—cyclosporine inhibits the calcineurin pathway in T cells—became tools for dissecting that pathway. Transplantation immunology made the case that the immune system's discrimination between self and non-self is not abstract; it is the barrier that must be crossed to save a patient with organ failure.
Allergy as IgE-Mediated Disease
Allergy had been recognized clinically since the nineteenth century—hay fever was described in 1819 by John Bostock—but its mechanism was unclear. The key discovery came in 1966–1967, when Kimishige and Teruko Ishizaka isolated a previously unknown class of immunoglobulin, IgE, from the serum of allergic patients, and showed that it mediated the Prausnitz–Küstner reaction (the transfer of sensitivity by serum, demonstrated in 1921). IgE binds to mast cells and basophils; when an allergen cross-links the bound IgE, the cells release histamine and other mediators, producing the immediate symptoms of allergy5. This explained why antihistamines worked, why allergen avoidance mattered, and why some patients could be desensitized by allergen immunotherapy—repeated exposure to increasing doses of allergen, which shifts the immune response away from IgE. The clinical management of allergy became a model of mechanism-based therapy: identify the antibody, block its effects, or modify its production.
Cellular and Molecular Translation: The Clinic Meets the Bench
From the 1970s onward, clinical immunology was transformed by the tools of cellular and molecular biology. Monoclonal antibodies, produced by Georges Köhler and César Milstein's hybridoma technique (1975), gave clinicians reagents of unprecedented specificity—first for diagnosis (identifying cell-surface markers on leukocytes, which became the CD nomenclature), then for therapy. Flow cytometry, developed in the 1970s, allowed clinicians to count and characterize immune cells in a patient's blood, making the diagnosis of immunodeficiency and leukemia far more precise. The ELISA (enzyme-linked immunosorbent assay), developed in the early 1970s, became the workhorse of clinical immunology laboratories, and its descendant, the ELISPOT, allowed the detection of individual antibody- or cytokine-secreting cells. Molecular biology added polymerase chain reaction (PCR) and gene sequencing, which made it possible to identify the specific genetic defects behind primary immunodeficiencies and to detect minimal residual disease in leukemia. By the 1990s, clinical immunology had become a discipline in which the laboratory and the clinic were in continuous conversation: a patient's unusual infection prompted a molecular investigation, and the molecular finding redefined the disease.
Biologic and Targeted Immunotherapy
The monoclonal antibody technique eventually produced a therapeutic revolution. Rituximab, approved in 1997, targeted the CD20 molecule on B cells and became a treatment for lymphoma and autoimmune diseases. Infliximab and other anti-TNF agents, approved in the late 1990s, blocked a cytokine central to inflammation and transformed the management of rheumatoid arthritis and inflammatory bowel disease. Checkpoint inhibitors—antibodies against CTLA-4 (ipilimumab, approved 2011) and PD-1/PD-L1 (approved from 2014)—released the brakes on T cells and produced durable remissions in some cancers, a discovery recognized by the 2018 Nobel Prize in Physiology or Medicine to James Allison and Tasuku Honjo. CAR T-cell therapy, in which a patient's T cells are engineered to express a chimeric antigen receptor, was approved in 2017 for certain leukemias and lymphomas. Each of these therapies descended from the same logic: identify a specific molecule that drives a pathological immune response, and target it with a designed biological agent. The clinical immunologist now works with a pharmacopoeia of engineered proteins and cells, and the boundary between immunology and oncology, rheumatology, and allergy has blurred accordingly.
Precision Immunodiagnostics and the Present
The most recent turn is toward precision immunodiagnostics: the use of high-dimensional measurements—flow cytometry panels with dozens of markers, gene-expression profiling, next-generation sequencing of immune repertoires, and multiplex assays of cytokines and autoantibodies—to characterize an individual patient's immune state. This approach descends directly from the serological and cellular methods of the twentieth century, but it aims at a finer resolution: not just "does this patient have an autoantibody?" but "which autoantibody, at what level, with what functional consequence, and in what cellular context?" The clinical problems that remain open are the ones the field has always faced. Why do some patients with the same autoantibody have different diseases? Why does immunotherapy work in some cancers and not others? How can immunosuppression be made specific enough to spare protective immunity? How should the immune system be monitored in patients receiving engineered cells? Clinical immunology today is a discipline of measurement and intervention, built on a century of learning that the immune system is both the body's defense and, when misdirected, its disease.
References
- Humoral immunity (History), Wikipedia
- Antibody (History), Wikipedia
- Anaphylaxis (History), Wikipedia
- Autoimmunity (History), Wikipedia
- Allergy, Wikipedia
The frameworks of Clinical Immunology
Each framework is a way of working the field has used: when it held, and the question it answers.
- 1897-1980
Immunochemistry and serological diagnosis
How can antibody-antigen reactions be read in the laboratory?
- 1902-1930
Serum therapy and serum sickness
Why do foreign sera sometimes make patients sick?
- 1942-Present
- 1945-Present
Transplantation immunology and immunosuppression
Why is a transplanted organ rejected, and how can it be stopped?
- 1952-Present
Primary immunodeficiency
What happens when a part of the immune system is missing?
- 1966-Present
IgE-mediated allergy model
What makes a harmless substance cause violent symptoms?
- 1975-Present
Cellular and molecular immunodiagnostics
How can immune cells and molecules be measured in disease?
- 1997-Present
Biologic and targeted immunotherapy
How can a drug be aimed at one immune molecule?
- 2010-Present
Precision immunodiagnostics
How can each patient's immune disorder be measured precisely?
How the ideas connect
Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.
Cellular and molecular immunodiagnostics grew out of Immunochemistry and serological diagnosis
ELISA and the other solid-phase immunoassays were built directly on the antibody-antigen precipitation and complement-fixation principles of immunochemistry, replacing the older readouts with enzyme labels. The serological laboratory's logic of interrogating serum with a known antigen carried straight into molecular immunodiagnostics.
Carried by Peter Perlmann; Eva Engvall; Rosalyn Yalow.
Precision immunodiagnostics grew out of Cellular and molecular immunodiagnostics
Precision immunodiagnostics grew out of molecular immunodiagnostics by adding genomic sequencing, multiplex assays and single-cell methods to the same antibody-antigen and cellular phenotyping logic. The later field is the refinement of the earlier diagnostic toolkit.
Autoimmunity influenced by Immunochemistry and serological diagnosis
The serological techniques of immunochemistry, especially complement fixation and later immunofluorescence, were turned on patients' own tissues and made autoantibodies visible. Coons's fluorescent antibody method grew directly out of the immunochemical labeling of antibody.
Carried by Albert Coons.
Primary immunodeficiency influenced by Immunochemistry and serological diagnosis
Bruton's recognition of agammaglobulinemia depended on the serum protein methods of immunochemistry, which could show the absence of the gamma globulin fraction. The diagnostic laboratory thus defined the first primary immunodeficiency.
Carried by Ogden Bruton.
IgE-mediated allergy model influenced by Serum therapy and serum sickness
The Prausnitz-Küstner transfer of sensitivity by serum, a product of the serum-sickness era's interest in serum-borne reactivity, was the phenomenon the Ishizakas explained when they isolated IgE. The earlier clinical observation of immediate serum reactions framed allergy as an antibody-mediated event.
Carried by Kimishige Ishizaka; Teruko Ishizaka.
Cellular and molecular immunodiagnostics influenced by Primary immunodeficiency
Characterizing primary immunodeficiencies required counting and phenotyping lymphocyte subsets, which led to flow cytometry and monoclonal antibody-based cellular diagnostics. The clinic's need to measure T and B cells pushed the molecular immunodiagnostic methods.
Carried by Max Cooper; Robert Good.
Cellular and molecular immunodiagnostics influenced by IgE-mediated allergy model
The measurement of allergen-specific IgE by radioallergosorbent test and related assays applied the new solid-phase immunoassay to the allergy model. IgE discovery gave the molecular diagnostics a defined target.
Carried by Kimishige Ishizaka.
Biologic and targeted immunotherapy influenced by Cellular and molecular immunodiagnostics
Monoclonal antibody technology and the molecular assays that characterized cell-surface markers made it possible to design targeted biologics such as rituximab and anti-TNF agents. The diagnostics identified the molecules that the therapeutics then attacked.
Carried by Georges Köhler; César Milstein.
Precision immunodiagnostics influenced by Biologic and targeted immunotherapy
Targeted biologics created the need to predict and monitor which patients would respond, driving biomarker-based precision diagnostics. The therapeutic program supplied the molecular targets that precision assays measure.
Cellular and molecular immunodiagnostics influenced by Transplantation immunology and immunosuppression
HLA typing for transplantation drove the development of serological and then molecular tissue-typing methods, which became part of the broader cellular and molecular immunodiagnostic toolkit. The need to match donor and recipient carried the immunochemical assay into the molecular era.
Carried by Jean Dausset.
Beyond the field
Where Clinical Immunology's ideas came from in other fields, and what they led to there: the strongest 12 of 95 links.
Immunochemistry and serological diagnosis influenced Serological Diagnosis and Serotaxonomy in Plant Virology
Plant serological diagnosis and serotaxonomy grew directly out of immunochemistry and clinical serology, adopting precipitation and agglutination methods for identifying plant viruses and bacteria.
Immunochemistry and serological diagnosis grew out of Humoral Immunity in Fundamental Immunology
The framework of quantitative immunochemistry and serological diagnosis grew directly out of the humoral immunity tradition established by von Behring, Ehrlich and the antitoxin work of the 1890s. Ehrlich's side-chain reasoning and the antigen-antibody specificity concepts of humoral immunity became the working vocabulary of serology.
Carried by Paul Ehrlich; Emil von Behring.
Immunochemistry and serological diagnosis led to Serological diagnosis in Disease Diagnostics
Serological diagnosis in the modern sense grew directly out of immunochemistry and the earlier serological methods developed from the 1890s onward, such as agglutination and complement fixation. The later diagnostic framework is a refinement of that immunochemical tradition.
Serum therapy and serum sickness influenced Allergy and Contact Dermatitis in Dermatology
Von Pirquet coined the term allergy in 1906 while studying serum sickness from serum therapy, and that clinical observation of altered reactivity became the core of the allergy concept.
Carried by Clemens von Pirquet.
Autoimmunity reacted against Horror Autotoxicus in Autoimmunity
Ehrlich's horror autotoxicus doctrine held that the organism could not produce antibodies against itself; the modern autoimmunity framework was framed precisely as a rejection of that prohibition, with the rheumatoid-factor and antinuclear-antibody demonstrations as the counter-evidence.
Carried by Paul Ehrlich.
Autoimmunity led to T-Cell-Mediated Autoimmunity in Neuroimmunology And Multiple Sclerosis
T-cell-mediated autoimmunity in multiple sclerosis is a branch of the general autoimmunity concept, which held that immune responses against self-antigens cause disease. The multiple sclerosis framework refined that general doctrine by identifying the T lymphocyte as the effector and by transferring disease with T cells in EAE.
Transplantation immunology and immunosuppression influenced Advanced Heart Failure and Transplant Medicine in Cardiology
Transplantation immunology and immunosuppression supplied the tissue-typing and drug therapy that cardiac transplant medicine depended on from Barnard's first operation onward.
Primary immunodeficiency influenced by Inborn Errors of Metabolism in Metabolic Nutrition
Garrod's inborn errors of metabolism provided the conceptual template for primary immunodeficiency: Bruton's agammaglobulinaemia was presented as an inborn error of a specific protein, and the field was subsequently framed as inherited defects of immune molecules and cells.
Carried by Archibald Garrod; Ogden Bruton.
Cellular and molecular immunodiagnostics influenced by Immunoglobulin structural biology in Fundamental Immunology
Elucidation of immunoglobulin domain structure by Edelman and Porter made possible antibody-based reagents and later monoclonal antibodies, the core tools of molecular immunodiagnostics. Hybridoma technology (Köhler and Milstein, 1975) built directly on this structural knowledge.
Carried by Gerald Edelman; Rodney Porter; Georges Köhler.
Cellular and molecular immunodiagnostics influenced by Quantitative Immunochemistry in Fundamental Immunology
Quantitative immunochemistry supplied the methods later cellular and molecular diagnostics rely on: radial immunodiffusion, immunoelectrophoresis and radioimmunoassay for measuring antigens and antibodies. These techniques, developed from the 1950s by Ouchterlony, Grabar and Yalow, became routine clinical assays.
Carried by Örjan Ouchterlony; Rosalyn Yalow.
Biologic and targeted immunotherapy influenced by Immunoglobulin structural biology in Fundamental Immunology
Knowledge of immunoglobulin structure underpinned the engineering of therapeutic antibodies, from chimeric and humanised forms to fully human antibodies used as biologic therapy.
Carried by Gerald Edelman; Rodney Porter.
Biologic and targeted immunotherapy influenced by Immune Regulation and Tolerance in Immunology
Understanding of immune regulation and tolerance, including checkpoint biology and regulatory T cells, provided the rationale for biologic therapies such as checkpoint inhibitors and tolerance-inducing agents.

Clinical Immunology is a planet in Nousfarer
Its city has a tower for each of these 9 frameworks. Land, walk in, and climb one concept at a time.
Land on Clinical ImmunologyRelated fields
Fields its ideas are linked to
- Fundamental Immunology 13 links
- Immunology 11 links
- Autoimmunity 10 links
- Neuroimmunology And Multiple Sclerosis 10 links
- Immunogenetics 6 links
- Dermatology 5 links
- Transplant Surgery 5 links
- Rheumatology 4 links
- Tumor Immunology 4 links
- Nephrology 3 links
- Systems Immunology 3 links
- Gastroenterology And Hepatology 2 links
More in Immunology
- Autoimmunity
- Fundamental Immunology
- Host Pathogen Immunology
- Immunogenetics
- Immunology
- Immunotherapy
- Systems Immunology
- Tumor Immunology
- Vaccinology
See where Clinical Immunology sits on the Map of Human Knowledge